Cancer Research Program – Fall 2020

Active Protocols by Disease Site

Research Investigators

May Hashimi, MD Hematology-Oncology
Stuart Krauss, MD Hematology-Oncology

Interim Director of Cancer Research/Research Nurse

Julie Koch, RN, BSN, OCN, CCRP
Phone: 708-763-2707
Cell: 708-238-7574

Research Nurse

Julie Koch, RN, BSN, OCN, CCRP
Phone: 708-238-7574

Regulatory Affairs

Carrie Hansen
Phone: 708-763-2719


Alliance A011401
Breast Cancer Weight Loss Study (BWEL Study) Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer NCT02750826

  • BMI > 27kg/m2 documented within 56 days prior to registration. Most recent BMI must be used for eligibility
  • Self-reported ability to walk at least 2 blocks (at any pace)
  • Histologically confirmed invasive breast cancer and registration must occur within 14 months after the first diagnosis
  • No history of invasive breast cancer in 5 years prior to registration other than the current diagnosis (prior DCIS at any time is acceptable)
  • All adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21 days prior to registration
  • All subjects must have sentinel lymph node biopsy and/or axillary lymph node dissection
  • Must meet comorbid conditions of the protocol
  • ECOG Status 0 or 1

Learn more about this National Colon Cancer Prevention Trial and read an FAQ to learn more.


SWOG S0820

Stage 0-IIIA Double-Blind Placebo-Controlled Trial of Eflornithine andSuldinac to Prevent Recurrence of High-Risk Adenomas and Stage 0-III Second Primary Colorectal Cancers in Patients with Colon or Rectal Cancer Phase III-Preventing Adenomas of the Colon with PACES NCT01349881